-
Je něco špatně v tomto záznamu ?
The heme catabolic pathway and its protective effects on oxidative stress-mediated diseases
Vítek L, Schwertner HA
Jazyk angličtina Země Spojené státy americké
Typ dokumentu přehledy
Grantová podpora
NR8186
MZ0
CEP - Centrální evidence projektů
Digitální knihovna NLK
Plný text - Část
Zdroj
- MeSH
- financování organizované MeSH
- hem metabolismus MeSH
- lidé MeSH
- nádory metabolismus MeSH
- nemoci cév metabolismus MeSH
- ochranné látky metabolismus MeSH
- oxidační stres genetika MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- přehledy MeSH
Bilirubin, the principal bile pigment, is the end product of heme catabolism. For many years, bilirubin was thought to have no physiological function other than that of a waste product of heme catabolism--useless at best and toxic at worst. Although hyperbilirubinemia in neonates has been shown to be neurotoxic, studies performed during the past decade have found that bilirubin has a number of new and interesting biochemical and biological properties. In addition, there is now a strong body of evidence suggesting that bilirubin may have a beneficial role in preventing oxidative changes in a number of diseases including atherosclerosis and cancer, as well as a number of inflammatory, autoimmune, and degenerative diseases. The results also suggest that activation of the heme oxygenase and heme catabolic pathway may have beneficiary effects on disease prevention either through the action of bilirubin or in conjunction with bilirubin. If so, it may be possible to therapeutically induce heme oxygenase, increase bilirubin concentrations, and lower the risk of oxidative stress-related diseases.
- 000
- 00000naa 2200000 a 4500
- 001
- bmc07527237
- 003
- CZ-PrNML
- 005
- 20150806124211.0
- 008
- 090817s2007 xxu e eng||
- 009
- AR
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Vítek, Libor, $d 1969- $7 xx0035071
- 245 14
- $a The heme catabolic pathway and its protective effects on oxidative stress-mediated diseases / $c Vítek L, Schwertner HA
- 314 __
- $a Fourth Department of Internal Medicine, Institute of Clinical Biochemistry, Laboratory Diagnostics, Charles University of Prague, U Nemocnice 2, Praha 2, 128 08 Prague, Czech Republic
- 520 9_
- $a Bilirubin, the principal bile pigment, is the end product of heme catabolism. For many years, bilirubin was thought to have no physiological function other than that of a waste product of heme catabolism--useless at best and toxic at worst. Although hyperbilirubinemia in neonates has been shown to be neurotoxic, studies performed during the past decade have found that bilirubin has a number of new and interesting biochemical and biological properties. In addition, there is now a strong body of evidence suggesting that bilirubin may have a beneficial role in preventing oxidative changes in a number of diseases including atherosclerosis and cancer, as well as a number of inflammatory, autoimmune, and degenerative diseases. The results also suggest that activation of the heme oxygenase and heme catabolic pathway may have beneficiary effects on disease prevention either through the action of bilirubin or in conjunction with bilirubin. If so, it may be possible to therapeutically induce heme oxygenase, increase bilirubin concentrations, and lower the risk of oxidative stress-related diseases.
- 650 _2
- $a financování organizované $7 D005381
- 650 _2
- $a hem $x metabolismus $7 D006418
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a nádory $x metabolismus $7 D009369
- 650 _2
- $a oxidační stres $x genetika $7 D018384
- 650 _2
- $a ochranné látky $x metabolismus $7 D020011
- 650 _2
- $a nemoci cév $x metabolismus $7 D014652
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Schwertner, Harvey A.
- 773 0_
- $w MED00182955 $t Advances in clinical chemistry $g Roč. 43(2007), s. 1-57 $x 0065-2423
- 910 __
- $a ABA008 $b x $y 7 $z 0
- 990 __
- $a 20090726182400 $b ABA008
- 991 __
- $a 20150806124308 $b ABA008
- 999 __
- $a ok $b bmc $g 672264 $s 531501
- BAS __
- $a 3
- BMC __
- $a 2007 $b 43 $d 1-57 $m Advances in clinical chemistry $x MED00182955 $i 0065-2423
- GRA __
- $a NR8186 $p MZ0
- LZP __
- $a 2009-B3/vtme